Shire (NASDAQ:SHPG)‘s stock had its “neutral” rating reissued by analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Tuesday.
A number of other analysts have also issued reports on the stock. Zacks Investment Research upgraded shares of Shire from a “sell” rating to a “hold” rating in a research note on Friday, October 27th. Royal Bank of Canada restated a “buy” rating on shares of Shire in a research note on Thursday, November 16th. Cantor Fitzgerald set a $222.00 price target on shares of Shire and gave the stock a “buy” rating in a research note on Thursday, November 16th. Bank of America lifted their price objective on shares of Shire from $236.00 to $237.00 and gave the stock a “buy” rating in a report on Monday, February 5th. Finally, Cowen set a $225.00 price objective on shares of Shire and gave the stock a “buy” rating in a report on Sunday, October 29th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and eleven have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $205.00.
Shares of Shire (NASDAQ:SHPG) opened at $134.06 on Tuesday. The company has a quick ratio of 0.52, a current ratio of 0.98 and a debt-to-equity ratio of 0.55. The stock has a market cap of $40,337.85, a price-to-earnings ratio of 9.54, a P/E/G ratio of 0.75 and a beta of 1.41. Shire has a 12 month low of $123.73 and a 12 month high of $192.15.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Delek Group Ltd. acquired a new position in shares of Shire during the fourth quarter valued at $19,478,000. Sawtooth Solutions LLC acquired a new position in shares of Shire during the fourth quarter valued at $200,000. Fore Capital LLC acquired a new position in shares of Shire during the fourth quarter valued at $527,000. APCM Wealth Management for Individuals acquired a new position in shares of Shire during the fourth quarter valued at $491,000. Finally, Lake Street Advisors Group LLC acquired a new position in shares of Shire during the fourth quarter valued at $286,000. 20.92% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://www.com-unik.info/2018/02/20/shires-shpg-neutral-rating-reiterated-at-jpmorgan-chase-co.html.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.